Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity

Reuters

2025/09/04

Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity

Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced interim results from its investigator-initiated Phase 2 Proof of Concept (PoC) study of VT-1953 topical gel, which is being tested in patients with malignant fungating wounds (MFW). The interim results were first presented at the annual meeting of the American Association for Cancer Research. The study showed that VT-1953 significantly reduced the primary endpoint of malignant fungating wound-associated malodor, with statistical significance (P<0.001). Additionally, patients reported significant improvements in secondary endpoints, including lesion pain and quality of life, both with statistical significance (P<0.001). Vyome Co-founder Dr. Shiladitya Sengupta will further discuss these preliminary results and the MFW market in a live video conference scheduled for Monday, September 8, 2025. Full study results are anticipated in October 2026, and Vyome plans to engage with the FDA in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904730668) on September 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564374798"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564374798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564374798?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564374798","market":"us","top_or_hot":-1,"title":"Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HIND\">Vyome Holdings, Inc.</a> (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced interim results from its investigator-initiated Phase 2 Proof of Concept (PoC) study of VT-1953 topical gel, which is being tested in patients with malignant fungating wounds (MFW). The interim results were first presented at the annual meeting of the American Association for Cancer Research. The study showed that VT-1953 significantly reduced the primary endpoint of malignant fungating wound-associated malodor, with statistical significance (P&lt;0.001). Additionally, patients reported significant improvements in secondary endpoints, including lesion pain and quality of life, both with statistical significance (P&lt;0.001). Vyome Co-founder Dr. Shiladitya Sengupta will further discuss these preliminary results and the MFW market in a live video conference scheduled for Monday, September 8, 2025. Full study results are anticipated in October 2026, and Vyome plans to engage with the FDA in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904730668) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-04 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HIND\">Vyome Holdings, Inc.</a> (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced interim results from its investigator-initiated Phase 2 Proof of Concept (PoC) study of VT-1953 topical gel, which is being tested in patients with malignant fungating wounds (MFW). The interim results were first presented at the annual meeting of the American Association for Cancer Research. The study showed that VT-1953 significantly reduced the primary endpoint of malignant fungating wound-associated malodor, with statistical significance (P&lt;0.001). Additionally, patients reported significant improvements in secondary endpoints, including lesion pain and quality of life, both with statistical significance (P&lt;0.001). Vyome Co-founder Dr. Shiladitya Sengupta will further discuss these preliminary results and the MFW market in a live video conference scheduled for Monday, September 8, 2025. Full study results are anticipated in October 2026, and Vyome plans to engage with the FDA in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904730668) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIND","symbol_name":"Vyome Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL82JHNs:1","article_id":"2564374798","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564374798","pubTimestamp":1756989072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire  on September 04, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIND":"Vyome Holdings, Inc.","BK4082":"医疗保健设备"},"translate_title":"Vyome Holdings宣布VT-1953治疗恶性真菌伤口的2期研究取得了令人鼓舞的中期结果，凸显了10亿美元的市场机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIND":0.9},"content_text":"Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity\n    \n\nVyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced interim results from its investigator-initiated Phase 2 Proof of Concept (PoC) study of VT-1953 topical gel, which is being tested in patients with malignant fungating wounds (MFW). The interim results were first presented at the annual meeting of the American Association for Cancer Research. The study showed that VT-1953 significantly reduced the primary endpoint of malignant fungating wound-associated malodor, with statistical significance (P<0.001). Additionally, patients reported significant improvements in secondary endpoints, including lesion pain and quality of life, both with statistical significance (P<0.001). Vyome Co-founder Dr. Shiladitya Sengupta will further discuss these preliminary results and the MFW market in a live video conference scheduled for Monday, September 8, 2025. Full study results are anticipated in October 2026, and Vyome plans to engage with the FDA in early 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904730668) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}